Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily

Leukemia and Lymphoma

Volumn 52, Issue 3, 2011, Pages 400-408

  Tholstrup, Dorte ^a   Brown, Peter De Nully ^a   Jurlander, Jesper ^a   Bekker Jeppesen, Palle ^b   Groenvold, Mogens ^c,d  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CHOP 14; Diffuse large B cell lymphoma; quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; APPETITE DISORDER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMOTION; FATIGUE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INSOMNIA; LARGE CELL LYMPHOMA; MALE; MENTAL FUNCTION; MORBIDITY; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; QUESTIONNAIRE; SOCIAL STATUS; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POPULATION; PREDNISONE; QUALITY OF LIFE; TIME FACTORS; VINCRISTINE;

EID: 79951692831     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.541310     Document Type: Article

References (38)

1. Wisloff F, Eika S, Hippe E, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92:604-613. (Pubitemid 26076761)
2. Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 1999;16:329-341. (Pubitemid 29496044)
3. Wisloff F, Kvam AK, Hjorth M, Lenhoff S. Serum calcium is an independent predictor of quality of life in multiple myeloma. Eur J Haematol 2007;78:29-34. (Pubitemid 46018555)
4. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-1678. (Pubitemid 47042371)
5. Alibhai SM, Leach M, Gupta V, et al. Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol 2009;69:168-174.
6. Messerer D, Engel J, Hasford J, et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008;93:826-833. (Pubitemid 351835978)
7. Savage E, Riordan O, Hughes M. Quality of life in children with acute lymphoblastic leukaemia: a systematic review. Eur J Oncol Nurs 2009;13:36-48.
8. Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007;139:255-264. (Pubitemid 47493093)
9. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 2005;46:1709-1714. (Pubitemid 43203103)
10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
12. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-1493.
13. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006. (Pubitemid 23095683)
14. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633. (Pubitemid 38970553)
15. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641. (Pubitemid 38970554)
16. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
17. Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19:545-552.
18. Trumper L, Zwick C, Ziepert M, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 2008;19:538-544.
19. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N.Engl.J.Med. 2002;346:235-242. (Pubitemid 34438862)
20. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
21. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881-893. (Pubitemid 36827204)
22. Tholstrup D, de Nully BP, Jurlander J, Hansen M. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Eur J Haematol 2007;79:100-106. (Pubitemid 47063255)
23. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496-502.
24. Halaas JL, Moskowitz CH, Horwitz S, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005;46:541-547. (Pubitemid 40584870)
25. Tholstrup D, Hansen M, de Nully Brown P, Jurlander J. Acquired immunodeficiency and malnutrition in patients treated with bi-weekly CHOP-based chemotherapy for diffuse large B-cell lymphoma. Blood 2006;108(Suppl. 1): Abstract 2443.
26. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009;114(Suppl. 1): Abstract 406.
27. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 2001;18:85-94. (Pubitemid 32906740)
28. Doorduijn J, Buijt I, Holt B, et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005;75:116-123. (Pubitemid 41008281)
29. Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2005;106(Suppl. 1): Abstract 13.
30. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC-30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
31. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993;2:129-140. (Pubitemid 23135397)
32. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997;50:441-450. (Pubitemid 27223274)
33. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
34. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ = C30 (+ 3). J Clin Oncol 1998;16:1188-1196. (Pubitemid 28108757)
35. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Using reference data on quality of life - the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 1998;34:1381-1389. (Pubitemid 28370930)
36. Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. New York: Wiley; 2007. pp 435-436.
37. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005;58:1217-1219. (Pubitemid 41608536)
38. Sprangers MAG. Response-shift bias: a challenge to the assessment of patients' quality of life in cancer clinical trials. Cancer Treat Rev 1996;22(Suppl. A):55-62.